Breast Cancer Clinical Trials

Trials for someone you care about with breast cancer.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

54 trials · showing 30

Comparing 3 approaches for HER2-positive breast cancer

Explore this study →

There are 3 groups in this study. Groups A and B receive RO7771950, together with one or more of: Trastuzumab and Capecitabine. Group C, the comparison group, receives Tucatinib, together with one or more of: Trastuzumab and Capecitabine.

Sites in Montreal, Toronto and 3 more cities

Phase 2
3 groups
Sites in Ottawa, Toronto and 3 more cities
Recruiting

Official title: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

HER2-positive Breast Cancer · Hoffmann-La Roche

Comparing Sacituzumab tirumotecan with Capecitabine for triple-negative breast cancer

Explore this study →

There are 2 groups in this study. Group A receives Pembrolizumab and Sacituzumab tirumotecan. Group B, the comparison group, receives one or more of: Pembrolizumab and Capecitabine.

Sites in Montreal, Toronto and 13 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 13 more cities
Recruiting

Official title: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer · Merck Sharp & Dohme LLC

Testing LY4064809 against a placebo for breast neoplasms

Explore this study →

There are 3 groups in this study. Groups A and B receive LY4064809, together with one or more of: Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane and Fulvestrant. Group C, the placebo group, receives Placebo, together with one or more of: Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane and Fulvestrant.

Sites in Hamilton, Québec and 2 more cities

Phase 3
3 groups
Sites in Hamilton, Québec and 2 more cities
Recruiting

Official title: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast Neoplasms · Eli Lilly and Company

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for breast cancer.

Comparing 5 approaches for breast neoplasms

Explore this study →

There are 5 groups in this study. Groups A, B, D and E receive LY4257496, together with one or more of: LY4257529. Group C receives LY4257496, together with one or more of: Standard of Care Anticancer Therapies and LY4257529.

Sites in Toronto, Hamilton and 1 more city

Phase 1
5 groups
Sites in Hamilton, Montreal and 1 more city
Recruiting

Official title: A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast Neoplasms · Eli Lilly and Company

Testing Inavolisib with CDK4/6i against a placebo for breast cancer

Explore this study →

There are 2 groups in this study. Group A receives Inavolisib, Letrozole and CDK4/6i. Group B, the placebo group, receives Placebo, Letrozole and CDK4/6i.

Sites in Montreal, Toronto and 7 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 7 more cities
Recruiting

Official title: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer · Hoffmann-La Roche

Testing Giredestrant for early breast cancer

Explore this study →

There are 2 groups in this study. Groups A and B receive Giredestrant.

One site, in Québec

Phase 3
2 groups
One site, in Québec
Recruiting

Official title: A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

Early Breast Cancer · Hoffmann-La Roche

Comparing [68Ga]Ga-DWJ155 with [177Lu]Lu-DWJ155 for breast cancer

Explore this study →

There are 2 groups in this study. Groups A and B receive one or more of: [68Ga]Ga-DWJ155 and [177Lu]Lu-DWJ155.

2 sites in Montreal

Phase 1
2 groups
2 sites in Montreal
Recruiting

Official title: Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

Breast Cancer · Novartis Pharmaceuticals

Comparing 5 approaches for advanced HR+/HER2- breast cancer

Explore this study →

There are 5 groups in this study. Group A receives IEV407. Groups B, D and E receive IEV407 and Fulvestrant. Group C receives IEV407 and Letrozole.

One site, in Toronto

Phase 1
5 groups
One site, in Toronto
Recruiting

Official title: Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Advanced HR+/HER2- Breast Cancer · Novartis Pharmaceuticals

Testing Inavolisib with Ribociclib against a placebo for breast cancer

Explore this study →

There are 2 groups in this study. Group A receives Inavolisib, Ribociclib and Fulvestrant. Group B, the placebo group, receives Placebo, Ribociclib and Fulvestrant.

Sites in Chicoutimi, Montreal and 2 more cities

Phase 2
2 groups
Sites in Ottawa, Toronto and 2 more cities
Recruiting

Official title: A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Breast Cancer · Hoffmann-La Roche

Comparing Patritumab deruxtecan with Paclitaxel for breast neoplasms

Explore this study →

There are 2 groups in this study. Group A receives Patritumab deruxtecan, together with one or more of: Rescue Medication. Group B, the comparison group, receives one or more of: Paclitaxel, Nab-paclitaxel, Capecitabine, Pegylated liposomal doxorubicin and Trastuzumab deruxtecan.

Sites in Toronto, Moncton and 2 more cities

Phase 3
2 groups
Sites in Moncton, Toronto and 2 more cities
Recruiting

Official title: A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms · Merck Sharp & Dohme LLC

Testing Pumitamig with Nab-paclitaxel/Paclitaxel against a placebo for breast neoplasms

Explore this study →

There are 2 groups in this study. Group A receives Pumitamig, together with one or more of: Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin and Eribulin. Group B, the placebo group, receives one or more of: Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin and Matching placebo.

Sites in Québec and Toronto

Phase 3
2 groups
Sites in Québec and Toronto
Recruiting

Official title: ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Breast Neoplasms · BioNTech SE

Comparing 4 approaches for advanced breast cancer

Explore this study →

There are 4 groups in this study. Group A receives Saruparib (AZD5305) and Camizestrant. Group B, the comparison group, receives one or more of: Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole and Exemestane. Group C receives Camizestrant, together with one or more of: Abemaciclib, Ribociclib and Palbociclib. …and 1 more groups.

Sites in Montreal, Toronto and 2 more cities

Phase 3
4 groups
Sites in Toronto, Greenfield Park and 2 more cities
Recruiting

Official title: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Advanced Breast Cancer · AstraZeneca

Testing Group 1-Isunakinra for triple-negative breast cancer (TNBC)

Explore this study →

There are 2 groups in this study. Group A receives Group 1-Isunakinra. Group B receives no study treatment and is followed for comparison.

One site, in Toronto

Phase 1
2 groups
One site, in Toronto
Recruiting

Official title: Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC

Triple-Negative Breast Cancer (TNBC) · University Health Network, Toronto

Comparing 5 approaches for advanced HR+/HER2- breast cancer

Explore this study →

There are 5 groups in this study. Group A receives GVV858. Groups B, D and E receive GVV858 and Fulvestrant. Group C receives GVV858 and Letrozole.

One site, in Toronto

Phase 1
5 groups
One site, in Toronto
Recruiting

Official title: Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast Cancer · Novartis Pharmaceuticals

Comparing Lasofoxifene in combination with with Fulvestrant in combination with for metastatic breast cancer

Explore this study →

There are 2 groups in this study. Group A receives Lasofoxifene in combination with abemaciclib. Group B, the comparison group, receives Fulvestrant in combination with abemaciclib.

Sites in Montreal, Ottawa and 2 more cities

Phase 3
2 groups
Sites in Ottawa, Toronto and 2 more cities
Recruiting

Official title: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Metastatic Breast Cancer · LeonaBio

Comparing 4 approaches for breast cancer

Explore this study →

There are 4 groups in this study. Groups A, B and C receive one or more of: GDC-4198 and Giredestrant. Group D receives one or more of: Giredestrant and Abemaciclib.

Sites in Toronto and Vancouver

Phase 1
4 groups
Sites in Vancouver and Toronto
Recruiting

Official title: A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Breast Cancer · Genentech, Inc.

Comparing 7 approaches for breast cancer

Explore this study →

There are 7 groups in this study. Groups A, B, C and D receive one or more of: Inavolisib, Ribociclib and Letrozole. Groups E, F and G receive one or more of: Inavolisib, Ribociclib and Giredestrant.

Sites in Montreal, Toronto and 1 more city

Phase 2
7 groups
Sites in Vancouver, Toronto and 1 more city
Recruiting

Official title: A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Breast Cancer · Hoffmann-La Roche

Comparing 3 approaches for breast cancer

Explore this study →

There are 3 groups in this study. Group A receives Inavolisib and Fulvestrant. Group B, the comparison group, receives Alpelisib and Fulvestrant. Group C receives Inavolisib and Fulvestrant, together with one or more of: Bupropion, Omeprazole and Midazolam.

Sites in Montreal, Calgary and 5 more cities

Phase 3
3 groups
Sites in Calgary, Edmonton and 5 more cities
Recruiting

Official title: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Breast Cancer · Hoffmann-La Roche

Comparing PF-07248144 with Everolimus for breast cancer

Explore this study →

There are 2 groups in this study. Group A receives PF-07248144 and Fulvestrant. Group B, the comparison group, receives Everolimus, together with one or more of: Fulvestrant and Exemestane.

Sites in Montreal, Québec and 3 more cities

Phase 3
2 groups
Sites in Edmonton, Ottawa and 3 more cities
Recruiting

Official title: A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Breast Cancer · Pfizer

Testing Ribociclib with Letrozole for early breast cancer

Explore this study →

Everyone in this study receives Ribociclib, together with one or more of: Letrozole, Ansastrozole, Goserelin, Leuprolide and Exemestane.

Sites in Montreal, Toronto and 6 more cities

Phase 3
1 group
Sites in Victoria, Halifax and 6 more cities
Recruiting

Official title: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Early Breast Cancer · Novartis Pharmaceuticals

Comparing 3 approaches for metastatic breast cancer

Explore this study →

There are 3 groups in this study. Group A receives Phesgo and Taxane-based Chemotherapy. Group B receives Inavolisib and Phesgo, together with one or more of: Optional Endocrine Therapy of Investigator's Choice. Group C, the comparison group, receives Placebo and Phesgo, together with one or more of: Optional Endocrine Therapy of Investigator's Choice.

Sites in Montreal, Calgary and 5 more cities

Phase 3
3 groups
Sites in Calgary, Moncton and 5 more cities
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer · Hoffmann-La Roche

Comparing 8 approaches for locally advanced breast cancer

Explore this study →

There are 8 groups in this study. Groups A, B, C, F, G and H receive BNT323 and BNT327. Group D receives BNT323. Group E receives BNT327.

Sites in Chicoutimi, London and 2 more cities

Phase 1
8 groups
Sites in Chicoutimi, London and 2 more cities
Recruiting

Official title: A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Locally Advanced Breast Cancer · BioNTech SE

Comparing Sacituzumab tirumotecan with Pembrolizumab for breast neoplasms

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine and Olaparib. Group B, the comparison group, receives one or more of: Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine and Olaparib.

Sites in Montreal, Barrie and 11 more cities

Phase 3
2 groups
Sites in Surrey, Vancouver and 11 more cities
Recruiting

Official title: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast Neoplasms · Merck Sharp & Dohme LLC

Comparing 3 approaches for triple negative breast neoplasms

Explore this study →

There are 3 groups in this study. Group A receives Sacituzumab tirumotecan, together with one or more of: Rescue Medication. Group B receives Sacituzumab tirumotecan and Pembrolizumab, together with one or more of: Rescue Medication. Group C, the comparison group, receives one or more of: Paclitaxel, Nab-paclitaxel, Gemcitabine and Carboplatin.

Sites in Montreal, Toronto and 5 more cities

Phase 3
3 groups
Sites in Edmonton, Oshawa and 5 more cities
Recruiting

Official title: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms · Merck Sharp & Dohme LLC

Comparing 3 approaches for breast neoplasms

Explore this study →

There are 3 groups in this study. Group A receives Sacituzumab tirumotecan. Group B receives Pembrolizumab and Sacituzumab tirumotecan. Group C, the comparison group, receives one or more of: Paclitaxel, Nab-paclitaxel, Capecitabine and Liposomal doxorubicin.

Sites in Montreal, Newmarket and 4 more cities

Phase 3
3 groups
Sites in Surrey, Newmarket and 4 more cities
Recruiting

Official title: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms · Merck Sharp & Dohme LLC

Comparing Tamoxifen with Camizestrant for early breast cancer breast cancer

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Tamoxifen, Anastrozole, Letrozole and Exemestane. Group B receives Camizestrant.

Sites in Montreal, Barrie and 10 more cities

Phase 3
2 groups
Sites in Calgary, Kelowna and 10 more cities
Recruiting

Official title: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Breast Cancer, Early Breast Cancer · AstraZeneca

Testing Neratinib for breast cancer

Explore this study →

Everyone in this study is in one group and receives Neratinib.

One site, in Toronto

Phase 2
1 group
One site, in Toronto
Recruiting

Official title: Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Breast Cancer · University Health Network, Toronto

Comparing 4 approaches for breast cancer

Explore this study →

There are 4 groups in this study. Group A receives AZD8205. Group B receives AZD8205 and AZD2936 (Rilvegostomig). Group C receives one or more of: AZD8205 and AZD5305 (saruparib) and AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig). …and 1 more groups.

Sites in Calgary, Montreal and 3 more cities

Phase 1
4 groups
Sites in Calgary, Vancouver and 3 more cities
Recruiting

Official title: A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Breast Cancer · AstraZeneca

Testing Sacituzumab Govitecan (SG) for advanced triple negative breast cancer

Explore this study →

Everyone in this study is in one group and receives Sacituzumab Govitecan (SG).

One site, in Vancouver

Phase 2
1 group
One site, in Vancouver
Recruiting

Official title: First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Advanced Triple Negative Breast Cancer · Nathalie Levasseur

Testing RYZ101 for metastatic breast cancer

Explore this study →

There are 2 groups in this study. Group A receives RYZ101. Group B receives one or more of: RYZ101 and Standard of Care Endocrine Therapy.

Sites in Toronto, Québec and 1 more city

Phase 1
2 groups
Sites in Victoria, Toronto and 1 more city
Recruiting

Official title: Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Metastatic Breast Cancer · RayzeBio, Inc.

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Breast Cancer trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.